Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

MNG64

b7d3faad-31cb-5416-9065-0241ef019cfd

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (0 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

No GSVA scores available for this sample.

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR12202486
bladder-landscape@3
0.911
2SRR8518409
breast-umap@18
D0.876
3TCGA-90-A59Q-01A-11R-A26W-07
lung-landscapes@6
cohortA10.872
4C3N-00433
lung-landscapes@6
cohortMD20.866
5MNG450
mng-umap@100
0.862
6be8d8236-4ebc-46de-a4fd-a901fec1cdce
melanoma-umap@29
0.853
7TCGA-MP-A4TJ-01A-51R-A262-07
lung-landscapes@6
cohortA10.851
8SRR8942969
bladder-landscape@3
0.850
9DRR168543
bladder-landscape@3
0.843
10TCGA-22-1005-01A-01R-0692-07
lung-landscapes@6
cohortMD20.842

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.595Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.545Idelalisib— uncovered
ALLOGRAFT_REJECTION0.540Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.441Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.300Inavolisib— uncovered
PANCREAS_BETA_CELLS0.244Cobimetinib— uncovered
COMPLEMENT0.195Inavolisib— uncovered
APICAL_SURFACE0.129Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.124Inavolisib— uncovered
MYOGENESIS0.103Inavolisib— uncovered
KRAS_SIGNALING_UP0.098Inavolisib— uncovered
IL2_STAT5_SIGNALING0.093Idelalisib— uncovered
COAGULATION0.088Binimetinib— uncovered
UV_RESPONSE_DN0.086Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.084Inavolisib— uncovered
KRAS_SIGNALING_DN0.062Remibrutinib— uncovered
APOPTOSIS0.040Idelalisib— uncovered
PEROXISOME0.013Idelalisib— uncovered
APICAL_JUNCTION0.002Inavolisib— uncovered